52 year old Post menopausal bleeding next management steps
Reading File
Finding Sources
Searching PubMed
"cervical cancer"[MeSH Terms] AND "chemoradiotherapy"[MeSH Terms] AND "stage IIB"
Searching the Web
cervical cancer stage IIB FIGO 2018 management CCRT guidelines 2024
Finding Sources
Searching PubMed
"uterine cervical neoplasms"[MeSH Terms] AND "chemoradiotherapy"[MeSH Terms]
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive information from the textbook and guidelines. Let me compile the full management plan.
Management: 52-Year-Old with Postmenopausal Bleeding — Ca Cervix Stage IIB
Summary of Findings
| Parameter | Finding |
|---|---|
| Histology | Moderately differentiated squamous cell carcinoma |
| Adverse features | Lymphovascular invasion (LVI) + perineural invasion |
| Tumor size (MRI) | 3.8 × 3.8 × 3.8 cm, bulky cervix |
| Parametrial involvement | Suspicious focal loss of stromal ring — ?parametrial invasion |
| Lymph nodes | Subcentimetric junctional nodes only (no definite metastatic nodes) |
| Adjacent organs | No bladder/rectal invasion; no hydronephrosis; no vaginal extension |
| FIGO Stage (2018) | IIB (parametrial involvement confirmed/suspected on MRI) |
Step 1 — Complete Workup Before Starting Treatment
Even with biopsy + MRI done, the following are needed:
- PET-CT scan (if available) — to evaluate pelvic and para-aortic lymph nodes more accurately (upstages to IIIC1/IIIC2 if nodes positive → changes radiation field)
- Chest X-ray / CT chest — to rule out distant metastases (Stage IVB)
- Full blood count, renal function (serum creatinine, eGFR), LFTs — baseline before cisplatin
- Audiometry — baseline before cisplatin
- Cystoscopy/proctoscopy — if clinical suspicion of bladder or rectal involvement (MRI here says none, but confirm clinically)
- Examination under anesthesia (EUA) — if clinical staging is uncertain
- HPV status — optional but informative
Step 2 — Definitive Treatment: Concurrent Chemoradiation (CCRT)
Stage IIB is NOT a surgical stage. The standard of care is:
Concurrent Cisplatin-Based Chemoradiation
"Chemoradiation is the preferred treatment strategy for these patients, with cisplatin the chemotherapy agent of choice." — Berek & Novak's Gynecology
Radiation:
- External beam radiation therapy (EBRT): 45–50.4 Gy in 25–28 fractions to the whole pelvis (IMRT/3D-CRT preferred to reduce bowel and bladder toxicity)
- Brachytherapy boost: High-dose-rate (HDR) intracavitary brachytherapy following EBRT — this is critical for local control; typically 5–6 Gy × 5 fractions or equivalent
Concurrent Chemotherapy:
- Weekly cisplatin 40 mg/m² (preferred regimen — GOG Protocol 120 confirmed superior OS vs. hydroxyurea alone)
- Given for ~5 cycles concurrent with EBRT
- Alternative if cisplatin-intolerant: carboplatin or 5-FU based regimens
Radiation field:
- Pelvis alone if nodes negative on PET/imaging
- Extended field (pelvis + para-aortic) if para-aortic nodes positive (Stage IIIC2)
Step 3 — Post-Treatment Surveillance
| Time | Assessment |
|---|---|
| 3 months post-treatment | MRI pelvis to assess response; clinical examination |
| Every 3 months × 2 years | Clinical exam, vault smear |
| Every 6 months × years 3–5 | Clinical exam |
| Annually thereafter | Clinical exam ± imaging |
| Symptoms of recurrence | CT/PET-CT |
Step 4 — Immunotherapy Consideration (2024 Update)
A 2024 systematic review (PMID 39351236) confirms that adding immune checkpoint inhibitors (pembrolizumab) to CCRT improves outcomes in locally advanced cervical cancer. The KEYNOTE-A18 trial established pembrolizumab + CCRT followed by pembrolizumab maintenance as a new standard in high-risk/locally advanced disease (FIGO 2014 stage III–IVA, or IB2–IIB with node positivity). This patient should be discussed at multidisciplinary tumor board (MDT) to consider immunotherapy eligibility if pembrolizumab is accessible.
Key Points Summary
- FIGO 2018 Stage IIB → NOT operable → CCRT is the definitive treatment
- Weekly cisplatin 40 mg/m² concurrent with pelvic EBRT 45–50.4 Gy + brachytherapy boost
- Complete pre-treatment workup: PET-CT, renal function, CBC
- LVI and perineural invasion are adverse prognostic features — reinforce need for complete CCRT
- Discuss at MDT; consider pembrolizumab if available (KEYNOTE-A18 data)
- No role for surgery at this stage
— Berek & Novak's Gynecology, Chapter on Cervical Carcinoma (Stage IIB management); SEOM-GEICO Clinical Guidelines 2024 (PMID 39215938)
This is a shared conversation. Sign in to Orris to start your own chat.